Mersana Therapeutics (MRSN) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
November 7, 2023 7:02 AM ESTAdvancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersanas B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersanas HER2 Immunosynthen ADCCapital resources expected to support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of... More
